FURI | Fall 2022

Analysis of Volatile Organic Compounds Specific to the Treatment of Small Cell Lung Cancer by Cisplatin and Etoposide

Health icon, disabled. A red heart with a cardiac rhythm running through it.

Lung cancer is the leading cause of cancer-related deaths globally, claiming 1.59 million lives annually. Numerous efforts have been made to reduce mortality, however, 33% of small cell lung cancer patients still experience a relapse within the first two years. This challenge is driven by limitations in diagnostics, which are unable to accurately evaluate the tumor treatment response over time. Due to altered biochemical pathways, I hypothesize that H345 cancer cells will have unique Volatile Organic Compounds (VOCs) expression under the administration of chemotherapeutics. The successful identification of treatment-responsive VOCs will enable the noninvasive evaluation of lung cancer treatments.

Student researcher

Youssef Abdellatif

Youssef H. Abdellatif

Biomedical engineering

Hometown: Cairo, Egypt

Graduation date: Spring 2023